Single Nucleotide Polymorphism (SNP) Genotyping: Technologies and Global Markets

Market Research Report | 2024-07-16 | 110 pages | BCC Research

AVAILABLE LICENSES:

- Single User License $5500.00
- 2-5 Users License $6600.00
- Site License $7920.00
- Enterprise License $9504.00

Report description:

Description

Report Scope:

This report covers the worldwide market for SNP genotyping, with the market segmented by technology and application. It provides an in-depth analysis of the SNP genotyping market, including estimates and trends through 2029. In this report, the market is divided into four regions: North America, Europe, Asia-Pacific and Rest of the World (RoW). For market estimates, data has been provided for 2023 as the base year, with forecasts for 2024 through 2029. This report also uses analytical frameworks such as PESTEL, examines the competitive landscape, and explores trends in ESG and funding.

Report Includes:

- 37 data tables and 44 additional tables
- An overview of the global market for single nucleotide polymorphism (SNP) genotyping
- Analyses of global market trends, with data from 2021-2023, estimates for 2024, and projected CAGRs through 2029
- Evaluation of the current market size and revenue growth prospects specific to SNP genotyping, along with a market share analysis by technology, application, and region
- Discussion of the advantages of the most frequently used SNP genotyping techniques, such as Sequenom's MassArray DNA analysis platform, Bruker's MALDI-TOF array, SNP pyrosequencing, microarrays and gene chips, and Applied Biosystems' (now part of Thermo Fisher Scientific) SNPlex and TaqMan
- Analysis of the regulatory framework and policies affecting the industry
- Discussion of the ESG practices of, as well as challenges for, companies
- Analysis of the key companies' market shares and their proprietary technologies, strategic alliances and patents
- Company profiles of the leading players, including Agilent Technologies Inc., F. Hoffman-La Roche Ltd., Illumina Inc., Qiagen, and

Thermo Fisher Scientific Inc.

Executive Summary

Summary:

Single nucleotide polymorphism (SNP) genotyping is a form of genotyping used to measure genetic variation. SNP, the most widely used form of genotyping, increases our understanding of the correlations between genotype and behavior exhibited by a living organism. SNP genotyping is generally used as a tool for identifying genomic variations and can lead to the determination of the health and ancestry of animals and plants. Increasing applications of SNPs in many areas is driving the market. However, diagnostics and pharmacogenomics represent the most attractive application areas for SNP genotyping. For SNP genotyping, several commercial platforms and methods have been developed.

SNPs cause phenotypic variations, influence the onset and course of many illnesses, and control how a gene reacts to medication and environmental stress. SNPs can also be molecular markers for determining the genes linked to significant biological traits and illnesses. Therefore, SNP profiling is important for pharmacological treatment, personalized medicine, agricultural productivity, and selective breeding. Alteration of a single nucleotide (A, T, C or G) in the genome sequence creates variations in the DNA sequence. A person's unique DNA pattern combines several SNPs. The ability to grasp and treat human sickness is advanced by SNPs, the most general genome mutations among all living things. SNP genotyping is the most prominent segment of the market and is inherent to genomics.

Table of Contents:

SCOTTS INTERNATIONAL

Single Nucleotide Polymorphism (SNP) Genotyping: Technologies and Global Markets

Market Research Report | 2024-07-16 | 110 pages | BCC Research

To place an Order with Scotts International:

- - Print this form
- - Complete the relevant blank fields and sign
- - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	$5500.00
	2-5 Users License	$6600.00
	Site License	$7920.00
	Enterprise License	$9504.00
	VAT	
	Total	

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*		Phone*	
First Name*		Last Name*	
Job title*			
Company Name*		EU Vat / Tax ID / NIP number*	
Address*		City*	
Zip Code*		Country*	
		Date	2026-03-05
		Signature